


Claims

1. A sulphonamide derivative of formula (I) or a physiologically acceptable salt thereof,

5



where

10 R_C is an optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or

R_C forms together with the phenyl ring to which it is attached a benzodioxolyl group, or

R_C is $-NR^1R^2$, where

R^1 is hydrogen or alkyl,



15 R^2 is alkyl or an optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or


R^1 and R^2 taken together with the nitrogen atom to which they are attached form a heterocyclic group, which may contain one or more additional heteroatoms selected from O and N and which may be substituted, or

20 R^1 and R^2 are absent and the nitrogen atom together with the adjacent carbon atom forms a heterocyclic ring, which may contain one or more additional heteroatoms selected from N, O and S and which may be substituted,

R_A is a group having the formula

25





wherein

5 n is 0 or 1, and
 R³ and R⁴ represent each independently hydrogen, halogen, aryl, alkoxy, carboxy, hydroxy, alkoxyalkyl, alkoxycarbonyl, cyano, trifluoromethyl, alkanoyl, alkanoylamino, trifluorometoxy, an optionally substituted aryl or heterocyclic group.

10 2. A derivative according to claim 1 where R¹ and R² represent methyl, R³ is 2-chloro and R⁴ is 4-chloro.

 3. A derivative according to claim 1 where R¹ is hydrogen, R² is 4,6-dimethylpyrimidin-2-yl, R³ is chloro and R⁴ is chloro.

15 4. A derivative according to claim 1 where R¹ and R² represent methyl, R³ is hydrogen and R⁴ is 3,4-dimethoxyphenyl.

 5. A derivative according to claim 1 where R¹ and R² represent methyl, R³ is hydrogen and R⁴ is 4-fluorophenyl.

 6. A derivative according to claim 1 where R¹ and R² represent methyl, R³ is hydrogen and R⁴ is bromo.

20 7. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide.

 8. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-sulfonic acid (2-methyl-benzooxazol-6-yl)-amide.

 9. A derivative according to claim 1, which is 2,4-dichloro-N-(1,2-dimethyl-1H-indol-5-yl)-N-methyl-benzenesulfonamide.

25 10. A derivative according to claim 1, which is 4'-fluoro-biphenyl-3-sulfonic acid (4-dimethylaminophenyl)-methyl-amide.

 11. A derivative according to claim 1, which is N-[4-(dimethylamino)phenyl]-4'-fluoro-2'-methyl-1,1'-biphenyl-3-sulfonamide.

30 12. A derivative according to any of claims 1 to 11 for use as an inhibitor for collagen receptor integrins.

 13. A derivative according to any of the claims 1 to 11 for use as an inhibitor for $\alpha 2\beta 1$ integrin.

14. A derivative according to any of claims 1 to 11 for use as an $\alpha 2\beta 1$ integrin I domain inhibitor.

15. A derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof for use as a medicament.


5 16. A derivative according to claim 15 for use as a medicament for treating thrombosis and cancer spread.

17. The use of a derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof for preparing a pharmaceutical composition for treating disorders relating to thrombosis and cancer spread.

10 18. A pharmaceutical composition comprising an effective amount of a derivative according to any of claims 1 to 11 or a physiologically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.


19. A process for preparing a benzene sulphonamide according to claim 1, comprising reacting a compound of formula (II)

15



where R_B , R_C and m are as defined above, with a compound of formula (III)

20



where R_A is as defined above and hal is halogen.